NCT07772531
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 13 words
- Trial sites reduced: 27 → 24 locations
- Minor Study sites: 26 to 27v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score
Timeframe: Up to Day 57
Secondary (4)
Number of Participants with Treatment Emergent Adverse Events (AEs)
Number of Participants with Serious Adverse Events (SAEs)
Number of Participants with AEs Leading to Treatment Discontinuation
Number of Participants with AEs Leading to Death
Arms and interventions
BMS-986511: Dose AExperimental
BMS-986511: Dose BExperimental
PlaceboExperimental
Drugs: BMS-986511, Placebo
Sites
24 sites in 2 countries
United States 18, Czechia 6